Gabriel T. Schnickel

ORCID: 0000-0003-4392-2200
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Organ Transplantation Techniques and Outcomes
  • Transplantation: Methods and Outcomes
  • Renal Transplantation Outcomes and Treatments
  • Liver Disease and Transplantation
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Organ Donation and Transplantation
  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • Chemokine receptors and signaling
  • Organ and Tissue Transplantation Research
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Immunotherapy and Immune Responses
  • Viral-associated cancers and disorders
  • HIV/AIDS drug development and treatment
  • T-cell and B-cell Immunology
  • Immune Response and Inflammation
  • Immune Cell Function and Interaction
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • Adenosine and Purinergic Signaling
  • Pancreatic and Hepatic Oncology Research
  • Heme Oxygenase-1 and Carbon Monoxide
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Liver Diseases and Immunity

University of California, San Diego
2019-2025

UC San Diego Health System
2024

Policlinico Umberto I
2023

University of Pennsylvania
2022

Penn Center for AIDS Research
2022

Henry Ford Hospital
2014-2019

Fundación Juan March
2016

Development Fund
2016

Creative Commons
2016

Henry Ford Health System
2013-2014

Ischemic cold storage (ICS) of livers for transplant is associated with serious posttransplant complications and underuse liver allografts.To determine whether portable normothermic machine perfusion preservation obtained from deceased donors using the Organ Care System (OCS) Liver ameliorates early allograft dysfunction (EAD) ischemic biliary (IBCs).This multicenter randomized clinical trial (International Randomized Trial to Evaluate Effectiveness Portable Preserving Assessing Donor Livers...

10.1001/jamasurg.2021.6781 article EN cc-by JAMA Surgery 2022-01-05

An accurate clinical assessment of hepatic steatosis before transplantation is critical for successful outcomes after liver transplantation, especially if a pathologist not available at the time procurement. This prospective study investigated surgeon's accuracy in predicting and organ quality 201 adult donor livers. A by blinded expert served as reference gold standard. The estimate correlated more strongly with large-droplet macrovesicular [ld-MaS; nonparametric Spearman correlation...

10.1002/lt.23615 article EN Liver Transplantation 2013-02-13

Immune checkpoint inhibitors (ICI) are increasingly used in patients with advanced hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). However, concerns about the risk of post-transplant rejection persist. We conducted an international retrospective cohort study including 119 HCC who received ICIs prior to LT. analyzed incidence allograft rejection, graft loss, and recurrence particular focus on washout period between last ICI dose In this study, 24 (20.2%) experienced a...

10.1097/hep.0000000000001289 article EN cc-by-nc-nd Hepatology 2025-03-05

HCC recurrence following liver transplantation (LT) is highly morbid and occurs despite strict patient selection criteria. Individualized prediction of post-LT risk remains an important need. Clinico-radiologic pathologic data 4981 patients with undergoing LT from the US Multicenter Transplant Consortium (UMHTC) were analyzed to develop a REcurrent Liver cAncer Prediction ScorE (RELAPSE). Multivariable Fine Gray competing analysis machine learning algorithms (Random Survival Forest...

10.1097/lvt.0000000000000145 article EN Liver Transplantation 2023-04-08

Immune checkpoint inhibitors (ICI) have been used to treat hepatocellular carcinoma (HCC) since 2017. The safety of ICIs in the setting solid organ transplantation remains controversial. When post-transplant setting, associated with high allograft rejection rates, but there are few published reports on use prior transplant. We present first reported case rescue liver re-transplantation after loss due severe acute extensive hepatic necrosis pre-transplant ICI therapy PD-1 inhibitor nivolumab....

10.1007/s12328-021-01521-4 article EN cc-by Clinical Journal of Gastroenterology 2021-10-13

Abstract Chemokine-chemokine receptor interactions orchestrate mononuclear cells recruitment to the allograft, leading acute and chronic rejection. Despite biologic redundancy, several experimental studies have demonstrated importance of CXCR3 CCR5 in rejection allografts. In these studies, deficiency or blockade led prolongation allograft survival, yet allografts were ultimately lost Given above findings specificity bearing CCR5, we hypothesized that combined will lead indefinite...

10.4049/jimmunol.180.7.4714 article EN public-domain The Journal of Immunology 2008-04-01

BACKGROUND:The aim of this study was to evaluate the outcome patients with intrahepatic cholangiocarcinoma (ICCA) incidentally found in explanted liver after transplantation. MATERIAL AND METHODS:We retrospectively reviewed 1188 recipients undergoing transplantation from August 2003 2014; 13 were have ICCA (1.1%). Recurrence-free survival (RFS) rate compared between and matched cohort 39 hepatocellular carcinoma (HCC). We also investigate relevance clinical pathological parameters recurrence...

10.12659/aot.895936 article EN Annals of Transplantation 2016-04-12

614 Background: Liver transplantation (LT) offers a 5-year survival exceeding 70% for selected patients with hepatocellular carcinoma (HCC). Immune checkpoint inhibitors (ICIs) may be used to downstage or bridge transplantation. This study aims evaluate the safety of ICIs prior LT. Methods: Multicenter retrospective study, involving 9 centers, included adults who received and, subsequent LT, between 2019 and 2023. The ICI cohort was matched by age, sex, liver diseases transplant date (1:3)...

10.1200/jco.2025.43.4_suppl.614 article EN Journal of Clinical Oncology 2025-01-27

The positive impact of platelets has been recently implicated in liver transplantation (LT). aim this study was to determine the risk factors for graft loss and mortality after LT, focusing on perioperative platelet counts.We reviewed all deceased donor LT from 2000 2012 enrolled 975 consecutive recipients. were analyzed by multivariate analysis, using Cox's regression model.Using cutoff values acquired receiver operating characteristics curve analyses determined that viral hepatitis C...

10.1111/ctr.12891 article EN Clinical Transplantation 2016-12-19

Background: The RETREAT score is a simple risk stratification tool for post-liver transplantation (LT) hepatocellular carcinoma (HCC) recurrence that has been validated in retrospective cohort studies. A prospective, multicenter study needed to further demonstrate accuracy especially given evolving clinical demographics and HCC transplant practice. Aim: To validate compare the other post-LT scores contemporary, prospective of patients Approach: We prospectively enrolled from 8 centers...

10.1097/hep.0000000000001297 article EN Hepatology 2025-03-11
Coming Soon ...